HK Stock Market Move | BIODLINK-B (01875) rose by over 11%, doubling its stock price for the year. WUXI XDC's acquisition offer is officially in effect.

BIODLINK-B (01875) rose by more than 11%, with the stock price doubling this year. As of the time of reporting, it rose by 9.94%, reaching 5.75 Hong Kong dollars, with a turnover of 210.874 million Hong Kong dollars. On the news front, WUXI XDC announced that their cash tender offer to acquire 60% of the shares in Dongyao Pharmaceutical has been accepted. The share offer is now in effect. Through this controlling acquisition, WUXI XDC will further enrich their project portfolio, expand their customer base, enhance production capacity, and continue to solidify their leading position in the global ADC CRDMO field. According to documents disclosed by the Hong Kong Stock Exchange, on March 17, WuXi XDC Cayman Inc. purchased 4.64 billion ordinary shares of Dongyao Pharmaceutical at an average price of 4.0 Hong Kong dollars per share, with a total value of approximately 1.855 billion Hong Kong dollars. After the purchase, their latest holdings amount to 4.64 billion shares, increasing their stake from 0.00% to 60.00%.